The Actual Situation and Challenges of Business Risk Management in Pharmaceutical Companies
Takeshi Eguchi ( The Office of Pharmaceutical Industry Research Senior Researcher)
(No.53: Published in March 2012)
In recent years, the pace of environmental change surrounding Japanese pharmaceutical companies has tended to accelerate. The pace of change in the business environment has been accelerating in recent years. The change to new drug discovery methods based on new technological fields such as biotechnology, the diversification of business into vaccines and generic drugs, and the full-scale entry into emerging markets have all led to moves to expand business domains and regions, and the increase in M&A for these purposes has increased the uncertainty in corporate activities. The number of mergers and acquisitions for these purposes has been increasing.
This study clarifies the actual status of business risk management mainly in domestic R&D-oriented pharmaceutical companies, including the characteristics of business risks, the level of importance, the implementation status of risk countermeasures, and risk management systems, based on the results of a survey of business risks disclosed in securities reports and a survey of departments in charge of corporate risk management. In addition, the report also discusses the risks that are considered to be important in the future and the issues that need to be addressed in terms of business risk management systems and operations.